Sequoia Receives FDA Fast Track Designation for UTI Vaccine

July 28, 2017

Sequoia Sciences received an FDA Fast Track designation for its vaccine for recurrent urinary tract infections caused by multidrug-resistant bacteria.

The vaccine recently completed its first clinical trial in women. Of the 67 patients enrolled, 30 had a two-year documented history of recurrent UTIs, a primary source of sepsis. The vaccine was well-tolerated and generated a strong immune response, the company said.

Sequoia cited a 2010 survey showing that 83 percent of urologists reported administering intravenous antibiotics to recurrent UTI patients that were resistant to all available oral antibiotics.

View today's stories